ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) Falls 4.18% as CXO Names Lead Declines

NewTimeSpace News: As of 10:46 on October 22, ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) stood at HKD 14.670, down 4.18%. The ETF opened at HKD 15.320, with the latest net asset value (NAV) at HKD 15.311, a discount of 0.01%, a 52-week high of HKD 17.040, a 52-week low of HKD 11.690, a turnover of approximately HKD 35.2442 million, and assets under management of approximately HKD 3.387 billion.

On the news front, Hong Kong stocks weakened broadly in morning trade. As of 10:56 on October 22, 2026, the Hang Seng Index fell 2.71%, and the Hang Seng TECH Index dropped 4.36%. The CXO sector led the declines, with Joinn Laboratories down 9.00%, Asymchem down 8.65%, and WuXi Biologics down 6.48%, as constituents across the sector fell across the board. In addition, the 2026 European Society for Medical Oncology (ESMO) Congress will kick off tomorrow (October 23), with 29 Chinese innovative drug studies selected as Late-Breaking Abstracts. Funds are taking profits and seeking safe havens ahead of key Phase III data disclosures, with innovative drug companies such as Zai Lab and Akeso also declining in tandem. On the individual stock front, Tigermed's subsidiary Frontage Holdings suspended trading this morning pending an announcement containing inside information, further amplifying market caution over uncertainties in the CXO chain.

From a medium-term perspective, the sector's fundamentals have not reversed. In the first three quarters, the total out-licensing value of Chinese innovative drugs reached approximately USD 130 billion, already close to the full-year level of last year. ChinaAMC Hang Seng Hong Kong Biotech Index ETF (03069.HK) closely tracks the Hang Seng Hong Kong Listed Biotech Index, with holdings covering innovative drug and CXO leaders such as BeiGene, Innovent Biologics, Akeso, and WuXi Biologics, serving as a concentrated tool to capture the resonance between sector sentiment and fundamentals.